What Визаллергол treats: Main Uses and Benefits

The medication is used in situations involving certain distressing symptoms linked to allergic responses in the eye. The medication is relevant for managing the signs and symptoms of allergic conjunctivitis. It is commonly used across domains where short-term symptomatic assistance is appropriate, helping to address symptom clusters that may appear suddenly or fluctuate.

The medication is used in conditions characterized by episodic or fluctuating symptom patterns, including seasonal allergic conjunctivitis and perennial allergic conjunctivitis. It is applied in addressing symptom clusters that may become disruptive, such as ocular itching, eye redness, watering, and a burning sensation.

Support During Acute Symptomatic Episodes

This medication is often used during phases when symptoms become more noticeable and supportive relief is needed, particularly during phases of heightened allergen exposure (e.g., peak pollen season). It contributes to improved comfort during periods of heightened symptoms, which may assist with maintaining functional stability when acute manifestations disrupt daily stability.

Quick Fact	Description
Support for Managing Ocular Pruritus	Helps address the core symptom of allergic response: eye itching.
Context	Applied in conditions involving recurrent and episodic allergic manifestations.
Benefit	Supports improved comfort during periods of heightened symptoms.

Regulatory References

1. NIH DailyMed Olopatadine Ophthalmic Solution

Who Can and Cannot Use Визаллергол?

Eligibility to use this ophthalmic solution (containing olopatadine) is strictly defined by official regulatory documents based on age, allergies, and physiological status.

Populations that MUST NOT Use the Medicine (Contraindications)

Classification	Population/Condition
Absolute Contraindication	Individuals with a known hypersensitivity or allergy to olopatadine hydrochloride or any of the product's inactive ingredients.

Eligibility by Age

Age Group	Eligibility Status (Regulatory)
Adults	Eligible for use.
Children ge 2 Years	Eligible for use (for 0.2% and 0.7% solution strengths).
Children ge 3 Years	Eligible for use (for 0.1% solution strength).
Children under 2 or 3 Years	Use not established; safety and effectiveness have not been demonstrated.

Use During Pregnancy and Lactation

Status	Regulatory Statement
Pregnancy	Use only if the potential benefit justifies the potential risk to the fetus; no adequate human studies have been performed.
Lactation (Breastfeeding)	Caution should be exercised when administered to a nursing mother. It is unknown if topical use leads to detectable quantities in human breast milk.

Other Restrictions

This medication must not be used to treat irritation related to contact lenses. Patients are directed to remove soft contact lenses prior to application and wait a specified time, typically at least 10–15 minutes, before reinserting them.

The interaction profile for Визаллергол (Olopatadine Ophthalmic Solution) is defined primarily by its minimal systemic absorption following topical application to the eye. This limited exposure is the basis for the official statement that interactions with medicinal products taken by mouth or injection are classified as unlikely in regulatory documentation.

Systemic Interaction Potential

Regulatory documentation indicates that olopatadine is not expected to cause clinically significant exposure-altering effects. In vitro studies confirm that olopatadine does not inhibit the activity of key cytochrome P-450 isoenzymes, including CYP 1A2, 2C8, 2C9, 2D6, and 3A4. Since plasma concentrations of olopatadine are typically negligible after ocular administration, the drug is not expected to alter the metabolism or systemic levels of co-administered drugs. No specific combinations with systemic products are formally contraindicated based on a pharmacokinetic or pharmacodynamic interaction mechanism.

Topical Co-Administration Rules

The only documented interaction rule is a procedural requirement for co-administered topical ocular products. When used in concomitant therapy with other topical ocular medicinal products, such as eye drops or eye ointments, a minimum separation interval of at least 5 minutes must be allowed between successive applications to ensure proper drug retention and therapeutic effect. Eye ointments must always be administered last in this sequence. No specific interaction patterns with food, alcohol, or herbal products are described in official regulatory labels.

Визаллергол (olopatadine) primarily acts as a selective histamine H1 receptor antagonist.

The drug molecules preferentially bind to the histamine H1 receptors on target cells, including those in ocular and nasal mucosa, competitivey preventing endogenous histamine from binding and activating the receptor. Histamine H1 receptor activation typically couples to Gq proteins, initiating the PLC ightarrow IP3/ DAG intracellular cascade, leading to the mobilization of intracellular Ca^2+ and subsequent activation of downstream pathways.

By functioning as an antagonist, olopatadine blocks this Gq-coupled signaling, which inhibits the release of various proinflammatory mediators, cytokines, and chemokines, such as tryptase and prostaglandin D2. This inhibition consequently reduces localized vasodilation and increased vascular permeability associated with the histamine-mediated response. Furthermore, olopatadine acts as a mast cell stabilizer, directly inhibiting the immunologically stimulated release of histamine and other pre-formed mediators from conjunctival mast cells. This dual pharmacodynamic action modulates both the initial release of inflammatory signals and the cellular response to residual histamine, resulting in a systemic physiological reduction in localized inflammatory cell chemotaxis and activation.

Визаллергол is administered exclusively via the Topical Ocular route, involving the instillation of drops directly onto the surface of the eye. The solution is not intended for injection or oral use.

Dosing and Frequency

The specific frequency of use is determined by the concentration of the ophthalmic solution:

Solution Strength	Dose per Affected Eye	Frequency
0.1%	One drop	Two times per day (BID)
0.2% and 0.7%	One drop	Once per day (QD)

For the twice-daily regimen (0.1% strength), the doses should be separated by an interval of approximately six to eight hours. The duration of use may extend up to four months when considered necessary.

Procedural Conditions and Population Rules

Specific procedures must be followed during instillation. If the medication is used alongside other topical ophthalmic products, at least a five-minute waiting period must be observed between administrations. To prevent contamination, the tip of the dropper must not touch the eye, eyelid, or any other surface.

Regarding contact lenses, soft lenses must be removed before applying the solution. Lenses may be re-inserted after a waiting period, typically 15 minutes. The minimum age for use is concentration-dependent: the 0.1% solution is approved for children aged three years and older, while the 0.2% and 0.7% solutions are approved for children aged two years and older. If a dose is missed, the instruction is to administer the dose as soon as the oversight is realized, but not to double the subsequent dose.

Research Evidence / Overview of Studies

Compound Target Research

Initial research focused on the compound’s biochemical target. Studies have investigated the change in patient-reported pain scales associated with the drug. Some studies reported a faster onset of findings when the drug was provided at the beginning of symptom flares.

---

Clinical Trial Data Summary

• Phase 1 Trials:
  • Early-stage research focused primarily on assessing the rate of adverse events and determining the maximum tolerated dose in healthy volunteers.
  • Results characterized the drug’s pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion.
• Phase 2 Trials:
  • Initial Phase 2 trials reported a quantifiable change in mobility scores across various patient cohorts.
  • These studies primarily explored various dosing regimens to identify a dose range for further investigation.
• Phase 3 Trials:
  • Multiple large-scale, randomized, placebo-controlled Phase 3 trials have explored the drug’s effects over a 12-week treatment period.
  • Outcomes measured included patient-reported pain scales (e.g., VAS and NRS) and functional assessments (e.g., ADL scores).
  • Research collected data on the occurrence of adverse events.

---

Special Population and Combination Studies

Studies examined whether co-administering the drug with standard physical therapy was associated with differences in reported pain and stiffness compared to physical therapy alone. This research investigated the findings on relevant clinical endpoints.

Research has investigated the absorption profile of the drug when provided alongside a meal. Studies have explored the drug’s metabolic pathway, including in participants with pre-existing liver conditions.

Common questions about Визаллергол (FAQ)

Q: Does Визаллергол treat the cause of allergy or just the symptoms?

According to official product information, Визаллергол (olopatadine) belongs to the group of H1-histamine receptor antagonists. This mechanism works by blocking the effects of histamine, a substance the body releases during an allergic reaction, which helps to relieve the visible symptoms of allergy.

Q: Can I use Визаллергол if I wear contact lenses?

Regulatory documents recommend removing soft contact lenses before use. This is because the product contains benzalkonium chloride, which may be absorbed by soft lenses. The product information specifies waiting 10 to 15 minutes after administration before re-inserting lenses.

Q: Is it normal to feel a brief sting or burning when I use the drops?

Studies and official product information list burning and stinging as very common side effects associated with the use of the drops, meaning they are observed in more than 1 out of 10 patients in clinical trials. Other commonly reported adverse reactions include eye pain, dry eye, and an abnormal sensation in the eye.

Q: How soon after I start using the drops should I expect my symptoms to improve?

Clinical studies and official product information indicate that olopatadine, the active ingredient, has a fast onset of action. The regulatory data suggests that treatment can provide relief from the symptoms associated with seasonal allergic conjunctivitis.

Q: If I miss a dose of the drops, what should I do?

The official instructions advise that if a dose is missed, it can be administered when remembered, unless it is nearly time for the next scheduled dose. In that case, the dose should be skipped, and the patient should continue with their regular schedule. The label explicitly states not to take a double dose to compensate for the missed one.

Q: What is the recommended storage temperature for the eye drops?

Official information states that the medicinal product does not require any special temperature storage conditions for storage. However, the regulatory information recommends keeping the container tightly closed and stored out of the reach of children.

Q: Is the Визаллергол bottle usable until it is completely empty?

The official product information specifies a shelf life for the eye drops after the bottle is first opened. The period of use specified by the manufacturer is four weeks after initial opening. After this period, any remaining product should be discarded to help maintain sterility and effectiveness.

The storage and disposal of Визаллергол (Olopatadine ophthalmic solution) are strictly defined by regulatory guidelines to ensure product stability and sterility.

Official Storage Requirements

Labeled Storage Temperature	Store at a controlled room temperature, generally between 4 C to 30 C (39 F to 86 F).
Container Protection	The bottle must be kept tightly closed when not in use. Do not allow the dropper tip to touch any surface.
In-Use Stability	The medicine must be discarded four weeks (28 days) after the container is first opened.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal Requirements

Regulatory information requires that unused or expired medicinal products and waste materials must be disposed of according to local requirements.

Do not throw away medicines via waste water or household waste unless instructed by local authorities.